BRCA1 and familial pancreatic carcinoma: PALB2 is involved in DNA damage response and repair together with BRCA1/2, and its mutations have been shown to increase risk for breast and pancreatic cancers.32,33 Treatments, such as PARP inhibitors and platinum agents, have been shown to improve clinical outcomes in PALB2 mutated breast and pancreatic patients.33,34 Potentially deactivating mutations in PALB2 may be the reason for the higher risk of progression within these patients.